Cancer/testis antigen 1 (53-62)

Cancer/testis antigen 1; NY-ESO-1

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.

CAT No: ta-495

Synonyms/Alias:Cancer/testis antigen 1 (53-62); NY-ESO-1 (53-62)

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
Sequence
ASGPGGGAPR
Areas of Interest
Antigen-presenting Cells; Cancer Research

Cancer/testis antigen 1 (53-62) is a synthetic peptide fragment derived from the immunodominant region of the cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. As a member of the cancer/testis antigen family, this peptide is characterized by its restricted expression pattern—typically limited to germ cells of the testis and aberrantly activated in a variety of malignancies. The 53-62 sequence represents a well-defined epitope recognized by cytotoxic T lymphocytes, making it a valuable tool for immunological studies focused on tumor antigens. Its precise sequence and immunogenic properties have established it as a model system for investigating antigen presentation, immune recognition, and peptide-based immunological assays.

Epitope mapping: Researchers utilize the 53-62 peptide fragment in epitope mapping studies to delineate the specific regions of CTAG1 recognized by T cells. By exposing immune effector cells to this defined peptide, investigators can systematically analyze T cell responses, helping to identify immunodominant epitopes and understand the molecular basis of tumor antigen recognition. Such mapping is essential for the rational design of immunotherapeutic strategies and for gaining insight into the specificity of anti-tumor immune responses.

T cell activation assays: The peptide serves as a standard reagent in T cell activation and proliferation assays. When presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells, it can stimulate antigen-specific cytotoxic T lymphocytes in vitro. These assays are instrumental for evaluating T cell functionality, studying antigen processing and presentation pathways, and optimizing conditions for immune monitoring in cancer research settings. The ability of the 53-62 epitope to elicit robust T cell responses makes it a preferred choice for such immunological assessments.

Peptide-MHC binding studies: The defined sequence of Cancer/testis antigen 1 (53-62) enables its use in quantitative and qualitative analyses of peptide-MHC interactions. Researchers employ this peptide to investigate binding affinities, stability, and presentation dynamics on various MHC class I molecules. These studies provide critical insights into the molecular determinants of antigen presentation, contributing to fundamental immunology research and informing the selection of target epitopes for further immunotherapeutic development.

Synthetic peptide library development: The 53-62 fragment is frequently incorporated into synthetic peptide libraries for high-throughput screening applications. Its inclusion allows for the evaluation of cross-reactivity, antigen mimicry, and the identification of T cell receptor (TCR) repertoires with specificity for CTAG1-derived epitopes. Such libraries are crucial for dissecting immune landscapes, profiling antigen-specific responses, and advancing peptide-based research methodologies in oncology and immunology.

Immunoassay calibration: The peptide is often employed as a positive control or standard in various immunoassays, including enzyme-linked immunospot (ELISPOT), enzyme-linked immunosorbent assay (ELISA), and flow cytometry-based detection of antigen-specific T cells. By providing a consistent and well-characterized antigenic stimulus, it supports assay validation, reproducibility, and quantitative comparison across experimental runs. This application is particularly valuable in translational research, where reproducible measurement of immune responses to tumor antigens is essential for both basic and applied scientific investigations.

Source#
Homo sapiens (human)
Epitope
53-62
Restricting HLA
HLA-A31
References
Wang; J Immunol 1998

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
cGMP Peptide ServiceCustom Conjugation ServicePeptide Modification ServicesPeptide Analysis ServicesEpitope Mapping ServicesPeptide CDMOPeptide Nucleic Acids SynthesisPeptide Synthesis Services
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers

Creative Peptides customer logo 1 Creative Peptides customer logo 2 Creative Peptides customer logo 3 Creative Peptides customer logo 4 Creative Peptides customer logo 5 Creative Peptides customer logo 6 Creative Peptides customer logo 7 Creative Peptides customer logo 8 Creative Peptides customer logo 9 Creative Peptides customer logo 10 Creative Peptides customer logo 11 Creative Peptides customer logo 12 Creative Peptides customer logo 13 Creative Peptides customer logo 14 Creative Peptides customer logo 15 Creative Peptides customer logo 16 Creative Peptides customer logo 17 Creative Peptides customer logo 18 Creative Peptides customer logo 19 Creative Peptides customer logo 20 Creative Peptides customer logo 21 Creative Peptides customer logo 22 Creative Peptides customer logo 23 Creative Peptides customer logo 24 Creative Peptides client partner 1 Creative Peptides client partner 2 Creative Peptides client partner 3 Creative Peptides client partner 4 Creative Peptides client partner 5 Creative Peptides client partner 6 Creative Peptides client partner 7 Creative Peptides client partner 8 Creative Peptides client partner 9 Creative Peptides client partner 10 Creative Peptides client partner 11 Creative Peptides client partner 12 Creative Peptides client partner 13 Creative Peptides client partner 14 Creative Peptides client partner 15 Creative Peptides client partner 16 Creative Peptides client partner 17 Creative Peptides client partner 18 Creative Peptides client partner 19 Creative Peptides client partner 20 Creative Peptides client partner 21 Creative Peptides client partner 22 Creative Peptides client partner 23 Creative Peptides client partner 24